Searching the Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Background: Previous studies have reported that the albumin-to-alkaline phosphatase ratio (AAPR), a novel blood biomarker-based index, is associated with clinical outcome in several cancers. However, data relating to lung cancer are rare. This study was performed to clarify the clinical significance of AAPR in patients with metastatic non-small-cell lung cancer (NSCLC). Methods: In total, 290 stage IV NSCLC patients were enrolled in this retrospective study. Associations between serum enzyme levels and clinical characteristics were analyzed using the Mann-Whitney U-test or chi-squared test. Kaplan-Meier survival analysis and Cox's proportional hazard regression model were adopted to assess the prognostic value of AAPR for overall survival (OS). Results: The optimal cut-off points for AAPR and lactate dehydrogenase (LDH) were 0.36 and 265.5 U/L, respectively. Patients with AAPR ≤0.36 had apparently longer survival than those with AAPR >0.36 (13 vs 7 months, P<0.001). Furthermore, AAPR was an independent predictor of OS in metastatic NSCLC in multivariate analysis (HR=0.657, 95% CI=0.504-0.856, P<0.01). The prognostic impact of LDH for survival of NSCLC populations was also validated in this study (HR=1.462, 95% CI=1.070-1.999, P<0.05). Conclusion: Elevated AAPR can be an independent favorable prognostic indicator in metastatic NSCLC.
Pubmed ID: 31303770
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Software package used for interactive, or batched, statistical analysis in social science, health sciences and marketing. Software platform offers advanced statistical analysis, a library of machine-learning algorithms, text analysis, open-source extensibility, integration with big data and deployment into applications.Versions that were produced by SPSS Inc. before the IBM acquisition (Versions 18 and earlier) would be given origin or publisher of SPSS Inc. in Chicago.
View all literature mentions